Browsing by Author "Ibrahim, Mohammed O"

Now showing 1 - 3 of 3

Abortive and Prophylactic Therapies to Treat Migraine in Pregnancy: A Review
(2024-10) Ibrahim, Mohammed O; Sarmini, Dana
Migraine is a common issue during pregnancy, often affected by hormonal changes. More than half of the women affected by migraine experience improvement in or remission of migraine symptoms, particularly during the second and third trimesters, with those having menstrual migraines or migraines without aura benefiting the most. However, a small percentage of women may see a worsening of their migraines, especially those with migraine with aura, and some may even develop migraines for the first time during pregnancy, often in the first trimester. Postpartum, many women experience a recurrence of migraines, likely due to the drop in estradiol and endorphin levels. A literature search was performed in PubMed for articles published from 2013 through 2023, and 80 out of 362 publications were included. When it comes to managing pregnant women with migraine, non-pharmacological treatments are preferred, including lifestyle modifications and avoiding known triggers. When medication is necessary, acetaminophen is the first-line treatment, with nonsteroidal anti-inflammatory drugs and triptans regarded as secondary options, though trimester-specific risks limit their use. Preventive treatments, if required, may include low doses of β-blockers or amitriptyline but should be used cautiously. This article aims to provide a concise overview of the existing research on the acute and prophylactic use of medications to treat migraines in pregnant and lactating women. Furthermore, it presents recommendations for healthcare professionals managing pregnant females presenting with migraine in clinical settings.
Abortive and Prophylactic Therapies to Treat Migraine in Pregnancy: A Review
(2024-10) Ibrahim, Mohammed O
Migraine is a common issue during pregnancy, often affected by hormonal changes. More than half of the women affected by migraine experience improvement in or remission of migraine symptoms, particularly during the second and third trimesters, with those having menstrual migraines or migraines without aura benefiting the most. However, a small percentage of women may see a worsening of their migraines, especially those with migraine with aura, and some may even develop migraines for the first time during pregnancy, often in the first trimester. Postpartum, many women experience a recurrence of migraines, likely due to the drop in estradiol and endorphin levels. A literature search was performed in PubMed for articles published from 2013 through 2023, and 80 out of 362 publications were included. When it comes to managing pregnant women with migraine, non-pharmacological treatments are preferred, including lifestyle modifications and avoiding known triggers. When medication is necessary, acetaminophen is the first-line treatment, with nonsteroidal anti-inflammatory drugs and triptans regarded as secondary options, though trimester-specific risks limit their use. Preventive treatments, if required, may include low doses of β-blockers or amitriptyline but should be used cautiously. This article aims to provide a concise overview of the existing research on the acute and prophylactic use of medications to treat migraines in pregnant and lactating women. Furthermore, it presents recommendations for healthcare professionals managing pregnant females presenting with migraine in clinical settings.
Electrochemical skin conductance to assess peripheral neuropathy in rheumatic diseases with or without type 2 diabetes using sudoscan
(2025-01-13) Ibrahim, Mohammed O
Introduction: Peripheral neuropathy (PN) occurs in diabetes mellitus. However, the association between PN and rheumatic disease (RD) has not been fully investigated. The aim of this study was to assess the prevalence of PN in patients with RDs with or without Diabetes Mellitus. Methods: A Cross‑sectional cohort study, data extracted from patients medical records started in September 2023 to January 2024 in Abu Dhabi, UAE. A Sudoscan machine report was used to assess The electrochemical skin conductance (ESC), Sudomotor dysfunction is evaluated according to the ESC measured on the feet: >60 µS = no dysfunction; 60–40 µS = moderate dysfunction; and <40µS = severe dysfunction. Results: Eighty‑one patients with RDs, mean age 58 ± 12. There were 55 females (67.9%), and 26 males (32.1%) attended an ambulatory healthcare clinic in Abu Dhabi, UAE. Thirty‑three (40.7%) had diabetes, while 48 (59.3%) did not have diabetes. The mean glycated haemoglobin A1c (HBA1c) was 7.4% in diabetic patients and 5.8% in non‑diabetic patients Additionally, all patients had a mean blood pressure of 134/72 and a mean Body Mass Index (BMI) of 31.40 kg/m2. Among the study patients, the most common RD was osteoarthritis, which affected 56.8% of the patients. The smallest percentage of patients with PN was found in those withIgG4, at 1.2%. The prevalence of Sudomotor dysfunction (ESC feet: <60 µS) was 72.8% in patients with RDs (all patients diabetic and non‑diabetic), while the prevalence of sudomotor dysfunction (ESC feet: <60 µS) in RDs patients with diabetes was 75.8% and 70.8% in RDs patients without diabetes, there was no significant difference between in prevalence of sudomotor dysfunction in RD patients with diabetes compared to RD patients without Diabetes. Conclusion: Sudomotor dysfunction appears to be common among patients with RD regardless they have diabetes or not. This study recommends screening all RD patients for Sudomotor Dysfunction.